{"id":"NCT02715726","sponsor":"Sanofi","briefTitle":"Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia","officialTitle":"A Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Ezetimibe in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Statin Therapy","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-07-27","primaryCompletion":"2018-08-06","completion":"2018-08-06","firstPosted":"2016-03-22","resultsPosted":"2019-09-30","lastUpdate":"2019-09-30"},"enrollment":615,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Hypercholesterolemia"],"interventions":[{"type":"DRUG","name":"Alirocumab","otherNames":["SAR236553 (REGN727)"]},{"type":"DRUG","name":"Placebo for alirocumab","otherNames":[]},{"type":"DRUG","name":"ezetimibe","otherNames":[]},{"type":"DRUG","name":"placebo for ezetimibe","otherNames":[]},{"type":"DRUG","name":"atorvastatin","otherNames":[]},{"type":"DRUG","name":"rosuvastatin","otherNames":[]},{"type":"DRUG","name":"simvastatin","otherNames":[]}],"arms":[{"label":"Ezetimibe 10 mg","type":"ACTIVE_COMPARATOR"},{"label":"Alirocumab 75 mg Q2W/up to 150 mg Q2W","type":"EXPERIMENTAL"}],"summary":"Primary Objective:\n\nTo demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable maximally tolerated daily statin therapy in comparison to ezetimibe 10 mg daily after 24 weeks of treatment in Asia in participants with hypercholesterolemia at high cardiovascular (CV) risk.\n\nSecondary Objectives:\n\n* To evaluate the effect of alirocumab 75 mg in comparison with ezetimibe 10 mg on LDL-C after 12 weeks of treatment.\n* To evaluate the effect of alirocumab on other lipid parameters: e.g., apolipoprotein B (Apo B), non-high density lipoprotein cholesterol (non-HDL-C), total cholesterol (TC), lipoprotein a (Lp\\[a\\]), HDL-C, triglycerides (TG), apolipoprotein A-1 (Apo A-1).\n* To evaluate the safety and tolerability of alirocumab.\n* To evaluate the development of anti-alirocumab antibodies.\n* To evaluate the pharmacokinetics (PK) of alirocumab.","primaryOutcome":{"measure":"Percent Change From Baseline in Calculated Low Density Lipoprotein Cholesterol at Week 24: Intent-to-treat (ITT) Analysis","timeFrame":"From Baseline to Week 24","effectByArm":[{"arm":"Ezetimibe 10 mg","deltaMin":-20.3,"sd":2},{"arm":"Alirocumab 75 mg Q2W/up to 150 mg Q2W","deltaMin":-56,"sd":1.5}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":9},"locations":{"siteCount":62,"countries":["China","India","Thailand"]},"refs":{"pmids":["31882376"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":23,"n":206},"commonTop":["Upper Respiratory Tract Infection","Accidental Overdose"]}}